KYNA-A1

KYNA-A1 is a synthetic analogue of **kynurenic acid** investigated as a modulator of glutamate signaling and as an experimental therapeutic in pain models, particularly migraine. KYNA-A1 acts as an antagonist at the NMDA (N-methyl-D-aspartate) receptor site, thereby inhibiting glutamatergic transmission. In rat studies, KYNA-A1 abolished nitroglycerin-induced hyperalgesia (pain sensitization), reduced the expression of calcitonin gene-related peptide (CGRP), neuronal nitric oxide synthase (nNOS), and key cytokines (such as TNF-alpha and IL-6) at peripheral and central trigeminal sites. These data support a role for KYNA-A1 as a central and peripheral modulator of pain transmission and neuroinflammation, particularly as a potential therapeutic candidate in migraine and hyperalgesia models[3][5][7].

Other names

kynurenic acid analogue 1